The winning work, conducted in collaboration with researchers at Brigham and Women's Hospital and Harvard Medical School, developed and validated a novel AI-driven metabolomics score to predict cardiovascular risk in patients with psoriasis. This work exemplifies the integration of cutting-edge artificial intelligence with translational cardiometabolic research, with the potential to guide prevention strategies in high-risk populations.
Dr Kotanidis said: 'It is an honour to receive this recognition from the ESC. I am grateful to my collaborators at Mass General Brigham and my RDM mentors Professor Charalambos Antoniades and Professor Stefan Neubauer for their invaluable guidance and support.'
Dr Kotanidis' research focuses on the application of data science and multi-modal integration of diverse datasets, including genomics, transcriptomics, radiomics, and metabolomics, to advance understanding of vascular inflammation and develop novel, non-invasive tools for characterising cardiovascular disease and guiding personalised therapy.
This achievement marks his second Young Investigator Award from the ESC, following his 2021 award in Coronary Pathophysiology and Microcirculation, which recognised work undertaken during his DPhil at Oxford with Professor Antoniades and Professor Keith Channon on redox-related human arterial transcriptomics to predict major adverse cardiac events and identify novel therapeutic targets.